Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (adrenal cortex cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: seviteronel, levoketoconazole, orteronel +3 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 2,032 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10466
Sealed predictions
- CYP17A1 in dopamine neurons, braak-0.37 (p 0.334) → -0.07 (p 0.859)receipt 10473
Swarm cases
receipt 10473: CYP17A1 in dopamine neurons, braak
- power
- full sample -0.26 (p 0.302, n 18), 95% CI -0.65 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.265, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.239, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.16, sign flips 0; without severely affected donors -0.26 (p 0.302, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP17A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts